Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

In Vitro Activity of the Type II Anti-CD20 Antibody GA101 in Refractory, Genetic High-Risk CLL.

Thorsten Zenz, Matthias Volden, Theresa Mast, Antonio Sarno, Dirk Winkler, Andrea Schnaiter, Andreas Bühler, Christian Klein, Pablo Umana, Hartmut Döhner, Stephan Stilgenbauer

Blood (2009) 114 (22): 2379.

https://doi.org/10.1182/blood.V114.22.2379.2379

Published: 2009

Journal Articles

In-Vitro Effect of the Small Molecule Thrombopoietin (TPO) Receptor Agonist Eltrombopag in Chronic Lymphocytic Leukemia (CLL).

Thorsten Zenz, Antonio Sarno, Andrea Schnaiter, Dirk Winkler, Andreas Bühler, Matthias Volden, Connie L. Erickson-Miller, Yasser Mostafa Kamel, Hartmut Döhner, Stephan Stilgenbauer

Blood (2009) 114 (22): 4408.

https://doi.org/10.1182/blood.V114.22.4408.4408

Published: 2009

Journal Articles

Detection of NFκB Activity in Primary CLL Cells Using a Sensitive Oligo-Based Chemiluminescent ELISA.

Daniel Mertens, Nupur Bhattacharya, Antonio Sarno, Irina Idler, Thorsten Zenz, Hartmut Döhner, Stephan Stilgenbauer

Blood (2009) 114 (22): 4709.

https://doi.org/10.1182/blood.V114.22.4709.4709

Published: 2009

Journal Articles

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial

Thorsten Zenz, Sonja Häbe, Tina Denzel, Julia Mohr, Dirk Winkler, Andreas Bühler, Antonio Sarno, Silja Groner, Daniel Mertens, Raymonde Busch, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer

Blood (2009) 114 (13): 2589–2597.

https://doi.org/10.1182/blood-2009-05-224071

Published: 2009

Includes: Supplemental data

Journal Articles

17p Deletion in CLL: Detailed Analysis of TP53 Mutations, Alternative Mechanisms of p53 Inactivation, Clone Size and Clonal Evolution

Thorsten Zenz, Antonio Sarno, Sonja Häbe, Tina Denzel, Julia Mohr, Dominik Vollmer, Maria Heuberger, Dirk Winkler, Dirk Kienle, Andreas Bühler, Sim Truong, Nancy Patten, Michael Hallek, Hartmut Döhner, Stephan Stilgenbauer

Blood (2008) 112 (11): 782.

https://doi.org/10.1182/blood.V112.11.782.782

Published: 2008

NARROW

In Vitro Activity of the Type II Anti-CD20 Antibody GA101 in Refractory, Genetic High-Risk CLL.

In-Vitro Effect of the Small Molecule Thrombopoietin (TPO) Receptor Agonist Eltrombopag in Chronic Lymphocytic Leukemia (CLL).

Detection of NFκB Activity in Primary CLL Cells Using a Sensitive Oligo-Based Chemiluminescent ELISA.

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial

17p Deletion in CLL: Detailed Analysis of TP53 Mutations, Alternative Mechanisms of p53 Inactivation, Clone Size and Clonal Evolution

Email alerts

ASH Publications

American Society of Hematology

In Vitro Activity of the Type II Anti-CD20 Antibody GA101 in Refractory, Genetic High-Risk CLL.

In-Vitro Effect of the Small Molecule Thrombopoietin (TPO) Receptor Agonist Eltrombopag in Chronic Lymphocytic Leukemia (CLL).

Detection of NFκB Activity in Primary CLL Cells Using a Sensitive Oligo-Based Chemiluminescent ELISA.

Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial

17p Deletion in CLL: Detailed Analysis of TP53 Mutations, Alternative Mechanisms of p53 Inactivation, Clone Size and Clonal Evolution

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only